GlassScriptPhysician profile
Regina Bell Mc Farland
NPI 1124371273
$1,547.32
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.16 · 2020: $13.13 · 2021: $26.55 · 2022: $217 · 2023: $770 · 2024: $312 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $830.11 | 2021-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $194.12 | 2023-2024 | Secuado |
| Tris Pharma INC | $114.02 | 2019-2025 | Dyanavel Xr |
| Mdd US Operations, LLC | $107.22 | 2023 | Myobloc |
| Corium, LLC | $62.38 | 2022 | |
| Ironshore Pharmaceuticals INC. | $50.93 | 2022-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $38.86 | 2020-2022 | |
| Axsome Therapeutics, INC. | $38.05 | 2025 | Auvelity |
| Neos Therapeutics, LP | $29.73 | 2024-2025 | Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $24.49 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.88 | 2025 | Relexxii |
| Allergan, INC. | $14.02 | 2019 | |
| Shire North American Group INC | $12.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Mc Farland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.